Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.250
+0.050 (4.17%)
At close: Sep 26, 2025, 4:00 PM EDT
1.230
-0.020 (-1.60%)
After-hours: Sep 26, 2025, 7:26 PM EDT
Allogene Therapeutics Stock Forecast
ALLO's stock price has decreased by -52.29% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for Allogene Therapeutics stock ranges from a low of $4.00 to a high of $14. The average analyst price target of $8.80 forecasts a 604.00% increase in the stock price over the next year.
Price Target: $8.80 (+604.00%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 1, 2025.
Analyst Ratings
The average analyst rating for Allogene Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 6 | 7 | 7 | 7 | 6 | 6 |
| Hold | 1 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 4, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 4, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $9 → $7 | Buy | Maintains | $9 → $7 | +460.00% | Aug 1, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +220.00% | May 15, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $14 → $10 | Strong Buy | Maintains | $14 → $10 | +700.00% | May 14, 2025 |
Financial Forecast
Revenue This Year
10.20K
from 22.00K
Decreased by -53.64%
Revenue Next Year
20.40K
from 10.20K
Increased by 100.00%
EPS This Year
-1.00
from -1.32
EPS Next Year
-0.94
from -1.00
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 105,000 | 105,000 | |||
| Avg | 10,200 | 20,400 | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 377.3% | 929.4% | |||
| Avg | -53.6% | 100.0% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.92 | -0.58 | |||
| Avg | -1.00 | -0.94 | |||
| Low | -1.18 | -1.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.